抗白细胞介素17生物制剂治疗银屑病有效性及安全性研究

Efficacy and Safety of Anti-interleukin-17 Biologics in the Treatment of Psoriasis

目的 探讨银屑病患者采用抗白细胞介素17生物制剂(司库奇尤单抗注射液)治疗的临床效果及安全性。方法 方便抽选2020年1月—2022年1月昆山市第一人民医院接诊治疗的248例银屑病患者为研究对象,根据就诊时间差异划分对照组(124例,2020年1—12月)与观察组(124例,2021年1月—2022年1月)。对照组采取常规方案治疗,观察组在其基础上采用抗白细胞介素17生物制剂治疗。比较两组患者治疗效果,观察评估两组患者治疗前后症状改善情况,检测两组患者治疗前后炎症因子水平变化,同时统计两组不良反应情况。结果 观察组患者治疗总有效率为98.39%,高于对照组,差异有统计学意义(χ^(2)=19.618,P<0.05)。治疗后,两组患者症状均有明显好转,观察组患者皮损面积、浸润程度、红斑、鳞屑症状评分均低于对照组,差异有统计学意义(P<0.05)。观察组治疗后IL-10高于对照组,IL-17低于对照组(P<0.05)。两组患者不良反应发生率对比,差异无统计学意义(P>0.05)。结论 银屑病治疗时可选择抗白细胞介素17生物制剂给予干预,能够有效改善患者症状表现,提高治疗效果,同时安全性理想,倡导运用推广。

Objective To investigate the clinical effect and safety of anti-interleukin-17 biologics(secuchiumab injection) in patients with psoriasis.Methods 248 patients with psoriasis who were treated by the First People′s Hospital of Kunshan City from January 2020 to January 2022 were conveniently selected as the study subjects.According to the difference in the time of treatment,the patients were divied into the control group(124 cases,January to December 2020) and the observation group(124 cases,January 2021 to January 2022) were divided.The control group was treated with conventional regimen,and the observation group was treated with anti-interleukin 17 biological agent on the basis of conventional regimen.Compared the treatment effect of the two groups of patients,observed and evaluated the improvement of symptoms of the two groups of patients before and after treatment,detected the changes of inflammatory factors in the two groups of patients before and after treatment,and counted the adverse reactions of the two groups.Results The total effective rate of treatment in the observation group was 98.39%,which was higher than that in the control group,and the difference was statistically significant(χ^(2)=19.618,P<0.05).After treatment,the symptoms of patients in both groups were significantly improved,and the score of skin lesion area,infiltration degree,erythema and scale symptom of patients in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).After treatment,IL-10 in the observation group was higher than that in the control group,while IL-17 was lower than that in the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion In the treatment of psoriasis,anti-IL-17 biologics can be selected for intervention,which can effectively improve the symptoms of patients,improve the therapeutic effect,and the safety is ideal,advocating the application and promotion.